** Shares of Immunome Inc IMNM.O down 10.2% to $8.40 post-market as biotech firm looks to raise equity
** Bothell, Washington-based oncology specialist commences $125 mln stock offering
** Co intends to use net proceeds to fund clinical and preclinical development of pipeline assets, and general purposes, per the SEC filing
** JP Morgan, TD Cowen, Leerink and Guggenheim are jt bookrunners
** With ~62.4 mln shares outstanding, IMNM has ~$583 mln market cap, per LSEG data
** Shares closed up 1.2% at $9.35 on Weds. Still, stock has lost 12% YTD and about 50% over the past 12 months
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。